Noticias de AIM_US

Noticias del mercado

Últimas noticias sobre AIM_US — 269 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.

Ticker: AIM_US ✕ 269 resultados
07/05/2026 AIM_US — Stock Titan
Ovarian cancer study reports 50% responses with 3-drug combo
07/05/2026 AIM_US — MarketScreener
Aim ImmunoTech announces 50% objective response rate (ORR) in UPMC recurrent ovarian cancer Phase 2 clinical trial, suggesting breakthrough combination potential
06/05/2026 AIM_US — GuruFocus
AIM ImmunoTech (STU:HXB) Dividends Received
28/04/2026 AIM_US — Finviz
AIM
28/04/2026 AIM_US — FinancialContent
AIM ImmunoTech Inc. Common Stock (NY: AIM
22/04/2026 AIM_US — tayninh.gov.vn
AIM ImmunoTech Inc. (AIM) posts wider than expected Q4 2025 loss, yet shares rise modestly in today’s trading. - Most Watched Stocks
22/04/2026 AIM_US — sonla.gov.vn
AIM ImmunoTech Inc. (AIM) posts wider than expected Q4 2025 loss, yet shares rise modestly in today’s trading. - Most Watched Stocks
20/04/2026 AIM_US — The National Law Review
AIM ImmunoTech Appoints David Chemerow to Board of Directors as an Independent Director
18/04/2026 AIM_US — ADVFN
AIM ImmunoTech Enters Pivotal Value Inflection Phase with Planned Phase 3 Study of Ampligen® in Pancreatic Cancer, Backed by Positive Clinical Signals, Orphan Drug Status, and Global IP
17/04/2026 AIM_US — Investing.com
AIM ImmunoTech advances Phase 3 planning for pancreatic cancer By Investing.com
17/04/2026 AIM_US — Investing.com
AIM ImmunoTech advances Phase 3 planning for pancreatic cancer By Investing.com
16/04/2026 AIM_US — GuruFocus ES ← EN
AIM ImmunoTech (AIM) avanza en los planes de tratamiento del cáncer de páncreas
16/04/2026 AIM_US — Investing.com
AIM ImmunoTech advances Phase 3 planning for pancreatic cancer By Investing.com
16/04/2026 AIM_US — GlobeNewswire
AIM ImmunoTech Enters Pivotal Value Inflection Phase with
16/04/2026 AIM_US — ChartMill
AIM ImmunoTech Enters Pivotal Value Inflection Phase with Planned Phase 3 Study of Ampligen® in Pancreatic Cancer, Backed by Positive Clinical Signals, Orphan Drug Status, and Global IP
16/04/2026 AIM_US — Yahoo Finance
AIM ImmunoTech Enters Pivotal Value Inflection Phase with Planned Phase 3 Study of Ampligen® in Pancreatic Cancer, Backed by Positive Clinical Signals, Orphan Drug Status, and Global IP
16/04/2026 AIM_US — newser.com
AIM ImmunoTech Inc. (AIM) posts wider than expected Q4 2025 loss, yet shares rise modestly in today’s trading. - Post Announcement
16/04/2026 AIM_US — newser.com
AIM ImmunoTech Inc. (AIM) posts wider than expected Q4 2025 loss, yet shares rise modestly in today’s trading. - Short Squeeze
16/04/2026 AIM_US — GlobeNewswire
AIM ImmunoTech Enters Pivotal Value Inflection Phase with
16/04/2026 AIM_US — Investing.com
AIM ImmunoTech advances Phase 3 planning for pancreatic cancer

Página 11 de 14

keyboard_arrow_up